Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.03, MarketWatch Earnings reports. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. The firm had revenue of $7.16 million for the quarter, compared to the consensus estimate of $6.96 million. During the same period in the previous year, the firm posted ($0.40) earnings per share.
Shares of Amicus Therapeutics (NASDAQ:FOLD) traded up 1.79% during midday trading on Friday, reaching $12.51. 3,424,906 shares of the company’s stock were exchanged. The company’s 50 day moving average is $12.55 and its 200-day moving average is $8.75. Amicus Therapeutics has a 12 month low of $4.41 and a 12 month high of $14.05. The stock’s market cap is $2.06 billion.
In other Amicus Therapeutics news, major shareholder Life Sciences Maste Perceptive acquired 1,500,000 shares of the business’s stock in a transaction dated Thursday, July 13th. The shares were purchased at an average cost of $12.25 per share, for a total transaction of $18,375,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jay Barth sold 30,000 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $10.00, for a total value of $300,000.00. Following the sale, the insider now owns 64,184 shares in the company, valued at $641,840. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Trexquant Investment LP purchased a new stake in Amicus Therapeutics during the first quarter valued at $496,000. UBS Asset Management Americas Inc. raised its stake in Amicus Therapeutics by 71.8% in the first quarter. UBS Asset Management Americas Inc. now owns 50,674 shares of the biopharmaceutical company’s stock valued at $361,000 after buying an additional 21,174 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Amicus Therapeutics by 12.5% in the first quarter. Bank of New York Mellon Corp now owns 672,463 shares of the biopharmaceutical company’s stock valued at $4,794,000 after buying an additional 74,700 shares in the last quarter. Princeton Alpha Management LP purchased a new stake in Amicus Therapeutics during the first quarter valued at $106,000. Finally, Canada Pension Plan Investment Board purchased a new stake in Amicus Therapeutics during the first quarter valued at $7,346,000.
COPYRIGHT VIOLATION WARNING: This piece was published by BNB Daily and is owned by of BNB Daily. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.baseball-news-blog.com/2017/08/19/amicus-therapeutics-inc-nasdaqfold-announces-earnings-results-updated.html.
FOLD has been the subject of several recent research reports. Zacks Investment Research cut shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 2nd. Robert W. Baird reiterated an “outperform” rating and set a $12.00 target price (up from $10.00) on shares of Amicus Therapeutics in a research note on Wednesday, May 17th. Bank of America Corporation cut their target price on shares of Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, May 25th. Chardan Capital reiterated a “buy” rating and set a $12.50 target price on shares of Amicus Therapeutics in a research note on Thursday, June 1st. Finally, ValuEngine upgraded shares of Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $14.58.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.